Towards Wnt inhibition without prohibitive toxicity

Towards Wnt inhibition without prohibitive toxicity

Wnt fuels cancer growth and drug resistance in millions of patients each year - yet any attempts to drug it have been blocked by toxicity.

Wnt fuels cancer growth and drug resistance in millions of patients each year - yet any attempts to drug it have been blocked by toxicity.

The Problem

Broad Wnt inhibition is overly toxic

Blocking Wnt signaling broadly leads to dose-limiting toxicity especially in gut and bone

Implicated across all major solid tumors

The Problem

Wnt drives cancer drug resistance

Blocking Wnt signaling broadly leads to dose-limiting toxicity especially in gut and bone

Implicated across all major solid tumors

The Limitation

Dose-limiting bottleneck

Narrow therapeutic window especially limiting in drug combinations

No approved Wnt inhibitor drug

The Limitation

Dose-limiting bottleneck

Narrow therapeutic window especially limiting in drug combinations

No approved Wnt inhibitor drug

The Innovation

Receptor Selective Inhibition

Targeting the specific Wnt receptor a tumor relies on for survival and resistance

Healthy tissue can rely on other receptors

The Innovation

Receptor Selective Inhibition

Targeting the specific Wnt receptor a tumor relies on for survival and resistance

Healthy tissue can rely on other receptors

The Opportunity

Engineered For Tolerability

First-in-class Wnt inhibitor molecule with a wide theraupetic window

Mono- and combination therapy potential

The Opportunity

Engineered For Tolerability

First-in-class Wnt inhibitor molecule with a wide theraupetic window

Mono- and combination therapy potential

Explore our preclinical data

Explore our

preclinical data

Book a call to meet a founder, learn more about our data, and discuss what selective Wnt inhibition could mean for oncology.

Book a call to meet a founder, learn more about our data, and discuss what selective Wnt inhibition could mean for oncology.

Phase 2

Phase 2

Phase 1

Phase 1

Pre-Clinical

Pre-Clinical

Research

Research

The Team

The Team

Pioneered by scientists with two decades and 8,000+ citations in Wnt research. Backed by business veterans.

Pioneered by scientists with two decades and 8,000+ citations in Wnt research. Backed by business veterans.

Precision medicine company advancing selective Frizzled (FZD) inhibitors to address dysregulated WNT signaling in cancer and drug-resistant diseases.

All Rights Reserved

Precision medicine company advancing selective Frizzled (FZD) inhibitors to address dysregulated WNT signaling in cancer and drug-resistant diseases.

All Rights Reserved

Precision medicine company advancing selective Frizzled (FZD) inhibitors to address dysregulated WNT signaling in cancer and drug-resistant diseases.

All Rights Reserved